Laureate Pharma Signs Manufacturing Agreement With Neoprobe

Neoprobe and Laureate Pharma (Laureate) have entered into a Biopharmaceutical Development and Manufacturing Agreement. Under the agreement, Laureate will assist in the development and production of Neoprobe’s murine monoclonal antibody CC49, called RIGScan CR.

RIGScan CR, a tumor-specific targeting agent initially intended for use in treatment of colorectal cancer. Terms of the development and manufacturing agreement were not disclosed.

Robert Broeze, president and CEO of Laureate, said: “We are delighted that Neoprobe has selected Laureate Pharma as their development and manufacturing partner. We will work closely in partnership with the Neoprobe biotech team and assist them in driving their product from development into the clinic.”